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Fumaric acid esters have proved to be effective for
the systemic treatment of severe psoriasis vulgaris.
These compounds have been shown to induce a
Th2-like cytokine secretion pattern in T cells and to
reduce keratinocyte proliferation in vitro. Dendritic
cells seem to be of major importance as regulatory
cells driving the psoriatic tissue reaction. Monocytes
or CD34-positive myeloid progenitor cells are
precursors of dendritic cells that can be generated
in vitro by culture with granulocyte-macrophage
colony-stimulating factor and interleukin-4. Using
this model the effect of fumaric acid esters on
granulocyte-macrophage colony-stimulating factor/
interleukin-4-induced differentiation of monocyte-
derived dendritic cells was investigated. The results
of this study show that dimethylfumarate as well as
methylhydrogenfumarate-calcium-salt (0.01±100 mg
perml) concentration-dependently inhibit monocyte-
derived dendritic cell differentiation. This was
re¯ected by an inhibition of CD1a, CD40, CD80,
CD86, and HLA-DR expression as well as by a
reduced capacity of dimethylfumarate-treated mono-
cyte-derived dendritic cells to stimulate lymphocytes
in the allogeneic mixed lymphocyte reaction. Other
fumaric acid esters showed no effect on monocyte-
derived dendritic cell-differentiation. At higher con-
centrations (30±100 mg per ml) dimethylfumarate, but
not methylhydrogenfumarate calcium-salt induced
apoptosis in monocyte-derived dendritic cells as
measured by expression of Apo 2.7 and DNA frag-
mentation (TUNEL assay). These data point to a
high susceptibility of the monocyte/dendritic cell
system to dimethylfumarate and its main metabolite
methylhydrogenfumarate. Other fumaric acid esters
investigated were without effect. As the effects
of fumarates on monocyte-derived dendritic cells
observed occur at concentrations 20-fold lower
compared with lymphocytes, our data seem to be of
relevance in explaining the possible mode of action
of these compounds in psoriasis. Key words: apoptosis/
dendritic cells/fumarate/psoriasis/treatment. J Invest
Dermatol 116:203±208, 2001
F
umaric acid esters (FAE) have been used for the systemic
treatment of psoriasis since 1959 (Schweckendiek, 1959).
At present the drug is registered in Germany; however,
registration is pending in many European countries. In
the beginning FAE were used on an empiric base. In
1994 the ®rst randomized, double-blind trial was published
con®rming previous open study results by showing reduction of
the psoriasis area and severity index of 80% in about 60% of the
treated patients (Altmeyer et al, 1994).
Evidence for a pharmacologic in¯uence of FAE on components
of the immune system was ®rst provided by demonstrating an
inhibition of lymphocyte proliferation by monoethylfumarate
(Petres et al, 1975). Recently, FAE were demonstrated to increase
production of interleukins (IL)-4 and -5 without changing the
production of IL-2 and interferon-g in stimulated peripheral blood
mononuclear cells (De Jong et al, 1996). In Th1/Th0 clones
challenged with bacterial antigen-enhanced secretion of IL-4 and
IL-5 could be induced by monomethylfumarate without affecting
interferon-g secretion (De Jong et al, 1996).
In human peripheral blood mononuclear cells, monomethyl-
fumarate increased production of IL-10, IL-1 receptor antagonist,
and tumor necrosis factor-a; however, the production of IL-12 was
not affected (Asadullah et al, 1997). Co-culture experiments using
keratinocytes from psoriasis patients and healthy controls together
with HUT78 T cells revealed inhibition of interferon-g secretion
and induction of IL-10 by dimethylfumarate (DMF) (Ockenfels
et al, 1998).
These data indicate that FAE may skew the Th1-dominated
immune response underlying the psoriatic tissue reaction towards a
Th2-type response.
Dendritic antigen-presenting cells are increased in number in
psoriatic lesions and are crucial in initiating a T cell mediated
immune response (Nestle et al, 1994). Furthermore, dendritic cells
are able to direct T cell development into a Th1- or Th2-like
pathway (Kalinski et al, 1999).
We have investigated whether FAE may modulate dendritic cell
differentiation and antigen-presenting activity. Our data provide
evidence for a high susceptibility of dendritic cells to DMF and
methylhydrogenfumarate (MHF) treatment. In concert with other
known immunomodulatory activities this may explain the
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bene®cial effect of DMF as the major ingredient of the marketed
drug and its main metabolite MHF in the treatment of psoriasis.
Additional experiments performed in order to investigate the
underlying mechanisms of this effect more closely point towards
the induction of apoptosis in dendritic cells by DMF.
MATERIALS AND METHODS
Culture medium and reagents The standard medium for cell culture
was RPMI 1640 (BioConcept, Umkirch, Germany) supplemented with
2 mM L-glutamine, 10% heat inactivated fetal bovine serum (BioConcept,
Umkirch), 100 U penicillin per ml, 100 mg streptomycin per ml. For
dendritic cell culture 100 U granulocyte-macrophage colony-stimulating
factor (GM-CSF) per ml (Leucomax, Novartis Pharma, NuÈrnberg,
Germany) and 10 ng IL-4 per ml (kindly supplied by Schering-Plough,
Kenilworth, NJ) was added to the supplemented medium.
Phycoerythrin- or ¯uorescein isothiocyanate-conjugated monoclonal
antibodies against the epitopes CD1a, CD14, CD40, CD80, CD86, and
HLA-DR as well as their respective isotype controls were from Coulter-
Immunotech (Krefeld, Germany).
The following fumaric acid esters (Merck, Darmstadt, Germany) were
used in this study: methylhydrogenfumarate (MHF), methylhydrogenfu-
marate calcium salt (Ca-MHF), ethylhydrogenfumarate magnesium salt,
ethylhydrogenfumarate calcium salt, DMF, fumaric acid, monoethylfuma-
rate, pentylhydrogenfumarate, and isopropylhydrogenfumarate. DMF was
dissolved in dimethyl sulfoxide and later diluted with standard medium, the
other FAE used were dissolved in standard medium. Dilutions of FAE were
prepared freshly and sterilized by ®ltration through 0.2 mM pore-size
membranes (Sartorius, GoÈttingen, Germany).
Except for DMF and Ca-MHF, FAE were used at a concentration of
10 mg per ml. DMF and Ca-MHF were employed at various concentrations
ranging from 0.01 to 100 mg per ml. Standard medium and DMSO were
equally tested as solvent control.
Generation of dendritic cells and cell culture Human puri®ed
monocytes were isolated by counter¯ow centrifugation elutriation from
peripheral blood mononuclear cells, obtained by Ficoll Paque (Biochrom,
Berlin, Germany) density gradient centrifugation of ethylenediamine
tetraacetic acid-anticoagulated venous blood from healthy donors after
informed consent. Purity of monocytes was assessed by cell-size analysis
(Coulter counter-channellyzer), and by microscopic evaluation of Giemsa-
stained cytospin preparations.
Monocytes were cultured at a density of 1.5±2 3 106 per ml in six-well
¯at bottom tissue-culture plates (Becton-Dickinson, Heidelberg, Germany)
at 37°C in a humidi®ed atmosphere with 5% CO2 in standard medium
together with GM-CSF and IL-4 to generate immature, in¯ammatory-type
monocyte-derived dendritic cells (Sallusto and Lanzavecchia, 1994).
Monocytes were treated from the beginning with FAE or DMSO (®nal
concentration 0.1%) or left with medium alone. Differentiation of dendritic
cells was controlled daily using an inverted microscope.
Flow cytometric analysis GM-CSF/IL-4-induced differentiation of
monocyte-derived dendritic cells and the effect of FAE on this process was
assessed by single color ¯ow cytometry. Analysis was performed using an
EPICS-XL ¯ow-cytometer and system II software (Coulter). Brie¯y, cells
were harvested after 5 d of culture and resuspended in phosphate-buffered
saline (PBS). Pelleted cells (5 3 105) in 100 ml PBS were incubated for
30 min at room temperature in darkness with antibodies against CD1a,
CD14, CD40, CD80, CD86, and HLA-DR as well as their corresponding
phycoerythrin-labeled or ¯uorescein isothiocyanate-labeled isotype control
antibodies to determine the level of background staining. At least 1 3 104
viable monocyte-derived dendritic cells per sample, gated according to
forward and side scatter characteristics, were analyzed.
Allogeneic mixed lymphocyte reaction (MLR) MLR was
performed using puri®ed allogeneic T cells as responder cells and
monocyte-derived dendritic cells as stimulator cells. Puri®ed T cells were
obtained by negative selection using the MACS-system (Miltenyi Biotech,
Bergisch Gladbach, Germany) employing monoclonal antibodies coupled
to magnetic beads against the following epitopes: CD11b, CD16, CD19,
CD36, and CD56. Brie¯y, 2 3 104 monocyte-derived dendritic cells after
5 d of culture in the presence of DMF (1.0 and 10 mg per ml) or DMSO
(0.01%, vol/vol) as solvent control were mixed with 5 3 104 responder
cells in a ®nal volume of 200 ml RPMI 1640 supplemented with 10% heat-
inactivated human AB serum, 2 mM L-glutamine, 100 U penicillin per ml,
100 mg streptomycin per ml and 10 mM HEPES in 96-well round-
bottomed microtiter plates (Costar, Bodenheim, Germany) at 37°C in a
humidi®ed atmosphere with 5% CO2 for 5 d. Three different monocyte-
derived dendritic cells/T cell ratios were investigated: 1:1, 1:10, and 1:100.
Proliferation of lymphocytes was assessed after addition of 1 mCi per well
[3H]thymidine (speci®c activity: 5 Ci per mmol; Amersham, Braunschweig,
Germany) for the last 24 h of culture. Cells were harvested on glass ®ber
with a semiautomated cell harvester apparatus (Skatron, Vienna, Austria)
and [3H]thymidine incorporation was measured in a liquid scintillation
spectrometer (Beckman, Munich, Germany). All experiments were
performed in triplicate and expressed as mean counts per minute (cpm)
6 SD.
Determination of apoptosis by ¯ow cytometry Flow cytometry was
used for detecting the cells undergoing apoptosis. Monocyte-derived
dendritic cells after 5 d of culture in the presence of DMSO or FAE were
harvested and washed twice with PBS. Then, 1 3 106 cells suspended in
100 ml of PBS were incubated for 30 min at room temperature in darkness
with a monoclonal antibody against Apo 2.7 (Coulter-Immunotech). To
exclude nonspeci®c staining, cells stained with corresponding isotype-
matched monoclonal antibodies were used as controls. For each sample, a
minimum of 10,000 cells, gated according to the forward and side scatter
characteristics, were analyzed.
Determination of apoptosis by the terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end-labeling (TUNEL)
method In order to verify apoptotic mechanisms induced in
monocyte-derived dendritic cells by FAE a second independent method
was used. TUNEL of nucleosomal DNA fragments with the commercially
available ``In Situ Cell Death Detection Kit'' (Boehringer Mannheim,
Mannheim, Germany) was employed according to the manufacturer's
protocol. This method was used to ensure a safe discrimination between
apoptosis and necrosis.
Statistical analysis Statistical analysis was performed from the data
obtained using the unpaired Student's t test. A p < 0.05 was considered
signi®cant.
RESULTS
Viability and purity of monocytes and monocyte-derived
dendritic cells Human monocytes showed a purity of greater
than 95% and a viability of > 98% after elutriation. After 5 d of
culture with GM-CSF/IL-4 the viability of monocyte-derived
dendritic cells was greater than 90% as judged by Trypan blue
exclusion.
Treatment of cells with FAE (up to 10 mg per ml) or DMSO
(0.01%, vol/vol) did not alter viability of monocyte-derived
dendritic cells. Using FAE in concentrations exceeding 50 mg
per ml monocyte-derived dendritic cells showed morphologic
changes (increased granularity, reduced dendrites) and viability
was decreased to about 75%.
Effect of FAE on the differentiation of monocyte-derived
dendritic cells Differentiation of monocyte-derived dendritic
cells by culturing monocytes for 5 d in standard medium with GM-
CSF/IL-4 was analyzed by ¯ow cytometry using monoclonal
antibodies against CD1a, CD14, CD40, CD80, CD86, and HLA-
DR. The results shown in Fig 1 demonstrate the typical CD1a/
CD40 (high), CD14 (low) monocyte-derived dendritic cells
phenotype as compared with monocytes. CD80, CD86, and
HLA-DR were also expressed on monocyte-derived dendritic
cells.
Treatment of monocytes with DMF (10 mg per ml), (Fig 1A) a
concentration not inducing signi®cant apoptosis (see below and
Fig 3) lead to a signi®cant decrease in cells expressing CD1a,
CD40, CD86, and HLA-DR. There was no change in CD14
expression by DMF. DMSO (0.01%, vol/vol) corresponding to a
FAE concentration of 10 mg per ml had no effect on the
differentiation of monocyte-derived dendritic cells. Figure 1(B)
demonstrate the effect of Ca-MHF (100 mg per ml) on MoDC
differentiation. The substance reduced expression of CD1a, CD40,
CD80, CD86, and HLA-DR signi®cantly. Interestingly, CD14-
expression was upregulated by Ca-MHF at this concentration,
indicating a pronounced shift of the cells to a monocyte/
macrophage phenotype. Furthermore, all other FAE investigated
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as well as fumaric acid had no effect on monocyte-derived dendritic
cells differentiation (data not shown).
Concentration-dependent inhibitory effect of DMF and
Ca-MHF on the differentiation of monocyte-derived
dendritic cells We next analyzed if the effect of DMF on
monocyte-derived dendritic cells differentiation was concentration
related. For comparison, the main DMF metabolite MHF in the
form of calcium salt was tested equally.
Figure 2 demonstrates concentration-dependent effects of DMF
and Ca-MHF (0.01±100 mg per ml) on CD1a, CD14 expression
and HLA-DR expression. A signi®cant inhibition of CD1a
expression was found for DMF at a concentration of 10 mg per
ml (p < 0.01) and 100 mg per ml (p < 0.001), respectively.
Expression of HLA-DR was signi®cantly reduced at all concentra-
tions used (p < 0.05).
Ca-MHF signi®cantly inhibited CD1a-expression at 1 and 10 mg
per ml (p < 0.05) and 100 mg per ml (p < 0.001), respectively. At a
concentration of 10 and 100 mg per ml expression of HLA-DR was
also reduced (p < 0.05). Ca-MHF, but not DMF, signi®cantly up-
regulated CD14 at 100 mg per ml (p < 0.05).
DMF inhibit the antigen-presenting function of monocyte-
derived dendritic cells Monocyte-derived dendritic cells
function as potent antigen-presenting cells and possess a high
capacity to stimulate lymphocytes in the MLR. As phenotypic
analysis showed that DMF inhibits differentiation (CD1a/CD40Ð
low) we analyzed the stimulatory capacity of DMF-treated
monocyte-derived dendritic cells in allogeneic MLR.
In comparison with solvent (DMSO) -treated control cells
[3H]thymidine uptake of puri®ed allogeneic T cells was decreased
in a concentration-dependent fashion after incubation with DMF-
treated monocyte-derived dendritic cells (Table I). Inhibition of
DMF-induced [3H]thymidine uptake was most pronounced using
monocyte-derived dendritic cells/T cell ratios of 1:1 and 1:10 in
comparison with the solvent control.
Induction of apoptosis by FAE As DMF and Ca-MHF in
concentrations above 50 mg per ml caused increased granularity,
reduced dendrites and decreased viability we asked whether these
morphologic alterations could be due to the induction of apoptosis.
To ensure a safe detection of apoptotic processes two independent
assay systems were employed.
Figure 1. Expression of CD1a, CD14, CD40,
CD80, CD86, and HLA-DR on MoDC and
its modulation by DMF and Ca-MHF. Mono-
cytes were isolated and cultured in the presence of
DMF (A) (10 mg per ml, nonapoptotic concentra-
tion) or Ca-MHF (B) (10 mg per ml) for 5 d
(shaded curves). A DMSO control for DMF
(0.01%, vol/vol) or a medium control for Ca-
MHF was included (open curves). Expression of the
epitopes was analyzed by single-color ¯ow cyto-
metry. One representative experiment of ®ve is
shown.
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As shown in Fig 3(A) DMF not Ca-MHF, however, induced a
concentration-dependent increase in the number of apoptotic cells
as determined by Apo 2.7 expression. At the highest concentration
of DMF used (100 mg per ml) more than 90% of monocyte-derived
dendritic cells stained positive for Apo 2.7 indicating induction of
apoptosis.
Using TUNEL as a second method to detect apoptosis DMF was
shown to induce DNA fragmentation in a concentration-
dependent manner (Fig 3B). At 100 mg per ml DMF about 80%
of monocyte-derived dendritic cells were demonstrated to be
apoptotic by terminal deoxynucleotidyl transferase labeling. Ca-
MHF-treated monocyte-derived dendritic cells showed no term-
inal deoxynucleotidyl transferase labeling, indicating DNA integ-
rity.
DISCUSSION
Fumaric acid esters have been found to be effective in the treatment
of psoriasis by empiric means (Schweckendiek, 1959). Meanwhile,
fumarates have successfully been used for more than 40 y, mainly in
Germany and in the Netherlands as a de®ned mixture of different
FAE, with DMF being the major compound. DMF is rapidly
hydrolyzed into MHF (also called monomethylfumarate), which is
regarded to be a major active metabolite. On the basis of the
chemical properties of DMF, this compound may penetrate cellular
membranes more easily as compared with Ca-MHF or MHF.
Several studies have been conducted to elucidate the mechanism
of action of FAE in the treatment of psoriasis and the results of these
investigations have been summarized recently (Mrowietz et al,
1999). MHF has been shown to stimulate tumor necrosis factor-a,
IL-10, and IL-1 receptor antagonist production in human
peripheral blood mononuclear cells without an effect on IL-12
secretion (Asadullah et al, 1997). Besides an antiproliferative effect
on keratinocytes (SeboÈk et al, 1994) and lymphocytes (Petres et al,
1975) in vitro, cells of the monocytic lineage seem to be an
additional important target for the action of FAE.
The results of our study show that DMF and its main in vivo
metabolite MHF as investigated by the use of its calcium-salt is able
to interfere with the differentiation of dendritic cells from
monocytes in vitro. DMF and MHF inhibited upregulation of the
Figure 2. Dose-related effect of DMF and
Ca-MHF on monocyte-derived dendritic
cells differentiation. Concentration dependence
of DMF and MHF-calcium-salt treatment on
CD1a, CD14, and HLA-DR expression on
monocyte-derived dendritic cells. Monocytes were
cultured for 5 d in the presence of various concen-
trations (0.01±100 mg per ml) of DMF and Ca-
MHF. The expression of CD1a, CD14, and
HLA-DR on monocyte-derived dendritic cells
was determined by ¯ow cytometry. Data represent
the mean 6 SD of ®ve separate experiments
(*p < 0.05; #p < 0.01; §p < 0.001).
Table I. Effect of DMF/DMSO treatment of monocyte-
derived dendritic cells on allogeneic MLR using different
effector/target-cell ratios and puri®ed T cells
Monocyte-derived DMSO (cpm) DMF (cpm) DMF (cpm)
dendritic cells/T cells (0.01%, vol/vol) (10 mg per ml) (1 mg per ml)
1:1 42192 25119 (59.5%a) 16141 (38.2%)
1:10 53754 27058 (50.3%) 40298 (75.0%)
1:100 35623 31372 (89.0%) 37478 (107%)
acpm, counts per minute.
bPercentage of DMSO control.
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dendritic cell marker CD1a, the costimulatory molecules CD80
and CD86, CD40 and of the major histocompatibility complex
class II molecule HLA-DR. Most profound changes were observed
for CD1a and CD40 (Fig 1). DMF and Ca-MHF showed
concentration-dependent effects up to the highest concentration
of 100 mg per ml used. The phenotypical changes induced in FAE-
treated monocyte-derived dendritic cells were re¯ected function-
ally by an inhibition of antigen-presenting function by DMF as
analyzed in the MLR.
As compared with other in vitro effects of FAE, such as the
induction of IL-4/IL-5 in MHF-treated T cells, the effect of DMF
and Ca-MHF on monocyte-derived dendritic cells differentiation
was observed at a 20±200 times lower concentration (Mrowietz
et al, 1999).
To address the question if changes in cellular morphology
observed at higher concentrations of FAE (> 50 mg per ml) may be
due to the induction of apoptosis, we performed additional
experiments with DMF and Ca-MHF in concentrations up to
100 mg per ml. Apoptosis was measured by two independent
methods. The expression of the marker Apo 2.7 is a sensitive
measure to detect induction of apoptosis at an early stage (Zhang
et al, 1996). The TUNEL technique demonstrates DNA
fragmentation (Loo and Rillema, 1998). Using both methods it
could be shown that DMF concentration-dependently induced
apoptosis in monocyte-derived dendritic cells, whereas Ca-MHF
had no effect (Fig 3). From these results it may be concluded, that
the inhibition of monocyte differentiation by DMF at higher
concentrations may be due to the induction of apoptosis.
Dendritic cells are regarded to play a crucial part in the
pathogenesis of psoriasis. These cells are increased in number in
lesional skin and show enhanced immunologic activity (Nestle et al,
1993, 1994). In the light of recent evidence that psoriasis may be
caused by (auto)antigen(s) dendritic antigen-presenting cells will
drive the pathogenetic process (Valdimarsson et al, 1997;
Drakesmith et al, 2000). Therefore, targeting the dendritic cell
system seems to be an effective measure to treat psoriasis. As
dendritic cells do not proliferate in situ, precursors such as
monocytes or CD34+ myeloid progenitor cells are recruited from
the peripheral blood differentiating in the tissue into immunolo-
gically active cells (Muller and Randolph, 1999). GM-CSF/IL-4-
induced monocyte-derived dendritic cells represent so-called
immature dendritic cells, which home at sites of in¯ammation as
recently demonstrated (Barratt-Boyes et al, 1998). Inhibition of
monocyte-derived dendritic cell differentiation, therefore, may lead
to cells with a decreased immunologic activity as we have shown in
this study.
Recently, IL-10 was found to have bene®cial effects in patients
with severe psoriasis (Asadullah et al, 1998; Reich et al, 1998). As
demonstrated earlier IL-10 inhibited GM-CSF/IL-13-induced
differentiation of human monocytes into monocyte-derived
dendritic cells (Allavena et al, 1998). A reduction of CD1a
expression and an upregulation of CD14 as well as a reduced ability
of monocyte-derived dendritic cells to stimulate allogeneic T cells
in the MLR was found after IL-10 treatment. Further analysis
revealed, that IL-10 shifted GM-CSF/IL-13-induced dendritic cell
development towards a macrophage-like differentiation. Very
recently 1,25-dihydroxycholecalciferol, the active metabolite of
vitamin D3, was found to inhibit monocyte-derived dendritic cell
differentiation and T cell-stimulating capacity in the MLR (Penna
and Adorini, 2000; Piemonti et al, 2000). This, however, was not
described to be due to the induction of apoptosis.
The loss of antigen-presenting activity of monocyte-derived
dendritic cells as shown by the decreased ability to stimulate the
MLR after DMF treatment led to a decreased immunologic
activity. The inhibition of CD40 expression and the down-
regulation of CD80/CD86 may be directly linked to this effect
(Grewal and Flavell, 1998; van Kooten and Banchereau, 2000). As
this is achieved at a 20-fold lower concentration as compared with
other in vitro effects of FAE, such as the induction of IL-4 and IL-5
in Th1/Th0-clones, it may be of relevance in vivo. At higher
concentrations DMF seems to alter monocyte-derived dendritic
cells by inducing apoptosis. The induction of apoptosis as a possible
mechanism of action has been described for methotrexate
(Genestier et al, 1998) and ultraviolet light (Ozawa et al, 1999),
both regimens being effective in the treatment of psoriasis. Very
recently, DMF not other FAE, however, was found to induce
apoptosis in the lymphohistiocytic cell line U937 in a concentration
range of 30±100 mmol per liter (SeboÈk et al, 2000). These data fully
support the ®ndings observed in this study. The induction of
apoptosis in target cells by DMF in higher concentrations seems to
be a unique feature for this fumaric ester, as Ca-MHF and other
FAE at these concentrations did not induce apoptosis. Further
investigations are needed in order to de®ne more closely the effects
of FAE observed in this study with regard to the clinically proven
effectiveness of the compounds in the treatment of severe psoriasis.
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Figure 3. Effect of DMF and Ca-MHF on apoptosis of monocyte-
derived dendritic cells. Apoptosis of human monocyte-derived dendritic
cells induced by DMF or Ca-MHF (0.1±100 mg per ml) compared with
medium control or solvent (DMSO) control (maximum concentration
0.1%, vol/vol) as measured by the expression of Apo 2.7 (A) or by TUNEL
(B). Mean and SD, n = 5.
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